- Home
- HCI vs AVBP Comparison
HCI vs AVBP Comparison
Compare HCI & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- AVBP
- Stock Information
- Founded
- HCI 2006
- AVBP 2021
- Country
- HCI United States
- AVBP United States
- Employees
- HCI N/A
- AVBP N/A
- Industry
- HCI Property-Casualty Insurers
- AVBP
- Sector
- HCI Finance
- AVBP
- Exchange
- HCI Nasdaq
- AVBP NYSE
- Market Cap
- HCI 1.7B
- AVBP 862.8M
- IPO Year
- HCI N/A
- AVBP 2024
- Fundamental
- Price
- HCI $139.35
- AVBP $21.63
- Analyst Decision
- HCI Strong Buy
- AVBP Strong Buy
- Analyst Count
- HCI 4
- AVBP 8
- Target Price
- HCI $181.25
- AVBP $38.38
- AVG Volume (30 Days)
- HCI 165.9K
- AVBP 484.4K
- Earning Date
- HCI 08-07-2025
- AVBP 08-13-2025
- Dividend Yield
- HCI 1.15%
- AVBP N/A
- EPS Growth
- HCI 4.05
- AVBP N/A
- EPS
- HCI 10.46
- AVBP N/A
- Revenue
- HCI $759,870,000.00
- AVBP N/A
- Revenue This Year
- HCI $19.25
- AVBP $85.82
- Revenue Next Year
- HCI $4.08
- AVBP N/A
- P/E Ratio
- HCI $13.30
- AVBP N/A
- Revenue Growth
- HCI 20.95
- AVBP N/A
- 52 Week Low
- HCI $85.85
- AVBP $15.47
- 52 Week High
- HCI $176.40
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- HCI 30.31
- AVBP 47.74
- Support Level
- HCI $136.75
- AVBP $19.71
- Resistance Level
- HCI $147.68
- AVBP $22.32
- Average True Range (ATR)
- HCI 4.38
- AVBP 1.32
- MACD
- HCI -0.95
- AVBP -0.20
- Stochastic Oscillator
- HCI 15.20
- AVBP 31.89
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.